Novo Holdings

Novo Holdings

Novo Holdings

Pulse 2.0

Checkmate Pharmaceuticals (CMPI) Stock: Why The Price Increased Over 320% Today

Pulse 2.0

Inozyme Pharma (INZY) Stock: Why The Price Jumped Up Over 10.5% Today

Pulse 2.0 , MedCity News

Why Pfizer (PFE) Is Buying ReViral For Up To $525 Million

Pulse 2.0

Inozyme Pharma (INZY) Stock: Why The Price Increaseed Today

SiliconBeat

Pac-12 partners with Tempus Ex Machina on data deal, paving the way for a vital new revenue stream

MedCity News

Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia

Pulse 2.0

Spruce Biosciences Stock (SPRB): Why The Price Jumped

CNET

Does Noom really work? These are the pros and cons of the trendy diet app

Pulse 2.0

Spruce Biosciences Stock (SPRB): Why The Price Surged

Fast Company

How $4 billion Noom co-opted the language of eating-disorder recovery to sell weight loss

Pulse 2.0

Inozyme Pharma (INZY) Stock: $23 Price Target From Needham

$21,000,000 Venture capital (Series A)
AFN

The Week in Agrifoodtech: Biomilq banks $21m; AeroFarms scraps SPAC

MedCity News

AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D

$90,000,000 Venture capital (Series B)
MedCity News

Blood disorder biotech Disc Medicine gets $90M to bring two drugs into Phase 2

$65,700,000 Venture capital (Series C)
TechCrunch

Southeast Asia “omnichannel” health startup Doctor Anywhere gets $88M SGD

$118,000,000 Venture capital (Series C)
Forbes Tech

In Latest Win For The Bio-Economy, Genomatica Raises $118 Million Led By Novo Holdings

PE HUB

Noom taps Goldman Sachs to lead IPO: Reuters

neurons.AI

EQRx puts Exscientia’s AI on drug discovery duty to develop low-cost cancer drugs

neurons.AI

Exscientia Enters Binding Agreement to Acquire Allcyte

neurons.AI

British AI drug discovery startup Exscientia buys Austrian cancer cell screening company